XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 26.06

+0.3%

Dec 26 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Webhead who wrote (3886)	9/24/1997 9:52:00 AM
From: aknahow	of 17367

You are correct. It is a phase one study for the CF antibiotic resistance patients, acording to Xoma's own words in the the meningococcemia info release. Agree it's not bad news but have some regrets that data on results of the phase III, thus far were not provided even in summary form. Perhaps there is an intent, by the DSMB, to avoid public pressure based on non scientific emotional response to what would be seen as good results rather than statistical analysis of a sufficient sample. At any rate how the stock will react is a moot point at this time.<g> REMINDER: DSMB according to first question of FAQ page says DSMB does not reveal the data to XOMA or other parties. I must assume this is true and so the lack of info after the meeting was to be expected. They could only say stop because it's not safe or go on because it is safe. At this point I wonder if the DSMB which is not the FDA could say stop because this works. Seems like only the FDA could say this and the FAQ implies or even states that the info is not released to anyone.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next